Abstract: One or more embodiments of the present specification provide a method and device for capacity degradation prediction of a lithium-ion battery. The method comprises the following steps: acquiring an original battery discharge capacity; decomposing the original battery discharge capacity through a predetermined mode decomposition method to obtain battery discharge capacities composed of a plurality of different frequency signals; inputting the respective frequency signals into a pre-constructed capacity prediction model to obtain capacity prediction results corresponding to the respective frequency signals; selecting capacity prediction result that satisfies a predetermined relevance condition corresponding to the respective frequency signals; and reconstructing the finally predicted battery discharge capacity according to the capacity prediction result that satisfies the predetermined relevance condition.

Abstract: One or more embodiments of the present description provide a method and device for risk prediction of thermal runaway in LIB. The method includes: acquiring knowledge of a mechanism for thermal runaway in LIB; describing an evolution process of thermal runaway in LIB by adopting a fault tree; mapping a fault tree structure to a dynamic Bayesian network model for thermal runaway in LIB to obtain quantitative results of a risk of thermal runaway in LIB; and taking the quantitative results of a dynamic Bayesian network as inputs of a machine learning model to obtain prediction results of the risk of thermal runaway. By using the method in the present embodiment, an evolution trend of battery thermal runaway can be predicted by fusing multiple thermal runaway causes and multi-source data, and thus, the prediction results are relatively accurate.

Abstract: A gas extraction device for metal mineral inclusions and a gas extraction method therefor are provided, the device includes a base plate, an annular carrier, sealing covers, a grinding assembly, a vacuum assembly, a gas-gathering assembly and a mass spectrometer. The annular carrier is disposed on the base plate, multiple grinding chambers are defined and evenly distributed in a circular shape on the annular carrier, the sealing covers are disposed at openings of the grinding chambers, the grinding assembly includes grinding hammers, and the grinding hammers penetrate through the sealing covers and extend into the grinding chambers. Side walls of each grinding chamber defines a first through hole and a second through hole. The vacuum assembly is communicated with the grinding chambers through the first through holes. The gas-gathering assembly is communicated with the grinding chambers through the second through holes. The mass spectrometer is communicated with the gas-gathering assembly.

Abstract: The three-state spintronic device includes: a bottom electrode, a magnetic tunnel junction and a top electrode from bottom to top. The magnetic tunnel junction includes: a spin-orbit coupling layer, a ferromagnetic free layer, a barrier tunneling layer, a ferromagnetic reference layer, three local magnetic domain wall pinning centers and domain wall nucleation centers. An antisymmetric exchange interaction is modulated, and the magnetic domain wall pinning centers are embedded in an interface between a heavy metal and the ferromagnetic free layer. The magnetic domain wall nucleation centers are at two ends of the ferromagnetic free layer. A current pulse flows through the spin-orbit coupling layer to generate a spin current and the spin current is injected into the ferromagnetic free layer. Under a control of all-electrical controlled, an effective field of a spin-orbit torque drives domain wall to move and displace.

Abstract: Embodiments of the present disclosure provide an optical imaging lens assembly that comprising, sequentially from an object side to an image side of the optical imaging lens assembly along an optical axis: a first lens having a negative refractive power, an object side surface of the first lens is convex surface and an image side surface of the first lens is a concave surface; a stop; a second lens having a positive refractive power, an object side surface of the second lens is a concave surface and an image side surface of the second lens is a convex surface; a third lens having a refractive power; a fourth lens having a refractive power, an object side surface of the fourth lens is a concave surface and an image side surface of the fourth lens is a convex surface. A relative illuminance RI corresponding to a maximal field-of-view of the optical imaging lens assembly satisfies: RI?50%; and at least one of the first lens to the fifth lens is a lens made of plastic material.

Abstract: Described herein is a composition for submucosal injection comprises a biocompatible modified starch and a pharmaceutically acceptable carrier for injection. The biocompatible modified starch is in an amount ranging from 0.2 wt % to 50 wt % of the total weight of composition. The biocompatible modified starch is selected from one or more of the group consisting of: etherified starches, esterified starches, cross-linked starches, pre-gelatinized starches, graft starches and composite modified starches, which has a molecular weight ranging from 3,000 to 2,000,000 daltons, a water absorbency capability of at least twice of its own weight, and a particle size from 500 nm to 1000 ?m. The viscosity of the composition ranges from 9 mPa·s to 150,000 mPa·s at 25° C. The present disclosure also provides a combination reagent for submucosal injection, comprising the above-mentioned biocompatible modified starch and the pharmaceutically acceptable carrier for injection.

Abstract: Disclosed herein is a biocompatible ultrasonic coupling agent for endoscopes, comprising a biocompatible modified starch and a pharmaceutically acceptable carrier, or comprising an ingredient selected from the group consisting of cellulose, polyvinylpyrrolidone, polyoxyethylene, sodium alginate, glucan, hyaluronic acid, chitosan, light sensitive glue, ultrasonic sensitive glue, pH sensitive glue, gelatin and carbomer, and a pharmaceutically acceptable carrier; wherein the ultrasonic coupling agent produces an acoustic characteristic impedance matching the acoustic characteristic impedance of the human tissues during use for endoscopic ultrasound examination. Disclosed herein is also a kit for endoscopic ultrasound examination, comprising the said biocompatible ultrasonic coupling agent.

Abstract: Described herein is a composition for submucosal injection comprises a biocompatible modified starch and a pharmaceutically acceptable carrier for injection. The biocompatible modified starch is in an amount ranging from 0.2 wt % to 50 wt % of the total weight of composition. The biocompatible modified starch is selected from one or more of the group consisting of: etherified starches, esterified starches, cross-linked starches, pre-gelatinized starches, graft starches and composite modified starches, which has a molecular weight ranging from 3,000 to 2,000,000 daltons, a water absorbency capability of at least twice of its own weight, and a particle size from 500 nm to 1000 ?m. The viscosity of the composition ranges from 9 mPa·s to 150,000 mPa·s at 25° C. The present disclosure also provides a combination reagent for submucosal injection, comprising the above-mentioned biocompatible modified starch and the pharmaceutically acceptable carrier for injection.

Abstract: Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 ?m to 2000 ?m and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.

Abstract: The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Abstract: Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 ?m to 2000 ?m and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.

Abstract: A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Abstract: The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Abstract: A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.